Supplementary Information

Altered transcriptomes, cell type proportions, and dendritic spine morphology in hippocampus of suicide deaths

Das, Sujan C.¹, Anton Schulmann², William B. Callor³, Leslie Jerominski⁷, Mitradas M. Panicker⁴, Erik D. Christensen³, William E. Bunney⁵, Megan E. Williams⁶, Hilary Coon⁷, Marquis P. Vawter^{1#}




Figure SF1: Major cell types for which the estimated cell type proportions were determined. Excit=Excitatory Neurons, Inhib=Inhibitory Neurons, Astro=Astrocytes, Oligo=Oligodendrocytes, OPC=Oligodendrocytes Progenitor Cells.




Figure SF2: The effect of age (A) and sex (B) on estimated cell type proportions of excitatory and inhibitory neurons. Excit=excitatory neurons, Inhib= inhibitory neurons, F=females, M=males.

		GO:0060079 - excitate	ory postsynaptic potential (49 genes) Scores: DESeq2_Final.txt co	l: 2 pvalue	
Cell Width: —	Color Range:	-0-			
Element	Score 🔺 QQ Score	Symbol	Name	Multifunc	QQ Multifunc
NPAS4	8.98e-06	NPAS4	neuronal PAS domain protein 4	0.745 (131)	
2RX6	5.48e-05	P2RX6	purinergic receptor P2X 6	0.687 (109)	
HRNA1	0.000642	CHRNA1	cholinergic receptor nicotinic alpha 1 subunit	0.805 (116)	
/EF2C	0.00159	MEF2C	myocyte enhancer factor 2C	0.997 (484)	
JLRA2	0.00566	GLRA2	glycine receptor alpha 2	0.893 (126)	
GRIN2C	0.00954	GRIN2C	glutamate ionotropic receptor NMDA type subunit 2C	0.826 (176)	
2RX4	0.0233	P2RX4	purinergic receptor P2X 4	0.953 (298)	
CHRNB1	0.0513	CHRNB1	cholinergic receptor nicotinic beta 1 subunit	0.731 (104)	
RRK2	0.0524	LRRK2	leucine rich repeat kinase 2	0.998 (673)	
LC29A1	0.0622	SLC29A1	solute carrier family 29 member 1 (Augustine blood group)	0.970 (104)	
PP3CA	0.0843	PPP3CA	protein phosphatase 3 catalytic subunit alpha	0.994 (486)	
GRIN2D	0.0921	GRIN2D	glutamate ionotropic receptor NMDA type subunit 2D	0.846 (189)	
MPP2	0.0921	MPP2	MAGUK p55 scaffold protein 2	0.331 (54)	
GRIN2B			glutamate ionotropic receptor NMDA type subunit 2B		
	0.104	GRIN2B MECP2		0.873 (252)	
MECP2	0.132		methyl-CpG binding protein 2	0.979 (398)	
ARRB2	0.136	ARRB2	arrestin beta 2	0.980 (399)	
2RX5	0.162	P2RX5	purinergic receptor P2X 5	0.679 (127)	
MAPK8IP2	0.189	MAPK8IP2	mitogen-activated protein kinase 8 interacting protein 2	0.723 (131)	
HRNA7	0.205	CHRNA7	cholinergic receptor nicotinic alpha 7 subunit	0.920 (266)	
CHRNB2	0.206	CHRNB2	cholinergic receptor nicotinic beta 2 subunit	0.956 (244)	
AB3GAP1	0.206	RAB3GAP1	RAB3 GTPase activating protein catalytic subunit 1	0.949 (177)	
GRIN2A	0.218	<u>GRIN2A</u>	glutamate ionotropic receptor NMDA type subunit 2A	0.924 (331)	
TRPV1	0.235	TRPV1	transient receptor potential cation channel subfamily V member 1	0.989 (340)	
CHRNA5	0.277	CHRNA5	cholinergic receptor nicotinic alpha 5 subunit	0.678 (102)	
OPRM1	0.299	OPRM1	opioid receptor mu 1	0.978 (260)	
GSK3B	0.302	GSK3B	glycogen synthase kinase 3 beta	0.988 (448)	
CHRNE	0.319	CHRNE	cholinergic receptor nicotinic epsilon subunit	0.564 (83)	
SEZ6	0.321	SEZ6	seizure related 6 homolog	0.480 (58)	
GRIK5	0.363	GRIK5	glutamate ionotropic receptor kainate type subunit 5	0.852 (180)	
JSK3A	0.374	GSK3A	glycogen synthase kinase 3 alpha	0.987 (453)	
SNCA	0.376	SNCA	synuclein alpha	0.998 (632)	
GRIN1	0.380	GRIN1	glutamate ionotropic receptor NMDA type subunit 1	0.910 (304)	
ADORA1	0.488	ADORA1	adenosine A1 receptor	0.996 (394)	
51PR2	0.505	S1PR2	sphingosine-1-phosphate receptor 2	0.770 (126)	
GLRA3	0.507	GLRA3	glycine receptor alpha 3	0.896 (116)	
CHRNA2	0.508	CHRNA2	cholinergic receptor nicotinic alpha 2 subunit	0.628 (90)	
IPFF	0.539	NPFF	neuropeptide FF-amide peptide precursor	0.327 (40)	<u> 1</u>
2RX2	0.547	P2RX2	purinergic receptor P2X 2	0.834 (176)	
DRD2	0.578	DRD2	dopamine receptor D2	0.999 (619)	
GRID2	0.587	GRID2	glutamate ionotropic receptor delta type subunit 2	0.830 (161)	
JHRL	0.595	GHRL	ghrelin and obestatin prepropeptide	0.999 (377)	
DK5	0.645	CDK5	cyclin dependent kinase 5	0.990 (580)	
KT1	0.718	<u>AKT1</u>	AKT serine/threonine kinase 1	0.997 (725)	
2RX7	0.839	<u>P2RX7</u>	purinergic receptor P2X 7	0.996 (571)	
GLRB	0.895	GLRB	glycine receptor beta	0.926 (141)	
CELF4	0.910	CELF4	CUGBP Elav-like family member 4	0.743 (148)	
CHRNA4	0.930	CHRNA4	cholinergic receptor nicotinic alpha 4 subunit	0.764 (141)	
CHRNA3	0.960	CHRNA3	cholinergic receptor nicotinic alpha 3 subunit	0.890 (184)	
GRIK2	0.971	GRIK2	glutamate ionotropic receptor kainate type subunit 2	0.928 (170)	

Figure SF3: Details of gene ontology term "GO:0060079-Excitatory Postsynaptic Potential"

Table ST1A: Demographics of subjects.

			p-value for statistical				
	Controls (CON)	Suicide Deaths (Sui)	difference				
N	28	22	N/A				
Sex	Male= 13, Female=15	Male= 12, Female=10	p=0.57				
Age (Mean, Std. Dev)	41.96 (15.41)	39.73 (15.40)	p=0.61				
RIN (Mean, Std. Dev),			p=0.97				
CA1 Tissues	5.41 (1.36)	5.43 (1.65)					
PMI (Mean, Std. Dev)	17.41 (6.99)	21.60 (7.02)	*p=0.04				
RIN, iPSC-derived NPC	9.5, 9.6	9.7, 9.8	N/A				
RIN, iPSC-derived			N/A				
Neurons	10, 10	9.9, 10					
RIN=RNA Integrity Number, PMI=Postmortem Interval, N/A=Not Applicable. Unpaired t-test for							
age, RIN, and PMI. Chi-square test for sex differences.							

Table ST1B: Detailed Demographics of Subjects.

		PMI	Manner of		
Sex	RIN	(Hours)	Death	Comorbidity	Toxicology
М	5.6	11	Natural	None Reported	None
М	3.1	19	Natural	Head Injury	Ethanol
М	3.8	17	Accident	None Reported	None
М	3.2	22	Natural	None Reported	None
М	6.2	28.35	Natural	Tremors	None
М	5.2	18	Accident	None Reported	None
М	5.9	15	Accident	None Reported	None
М	6.5	11.6	Accident	None Reported	Ethanol
М	3.1	17.36	Natural	None Reported	None
F	6.9	11.22	Accident	Mild Stroke	Ethanol, Caffeine, Cotinine, Naloxone
					Caffeine, Cotinine, Benzoylecgonine,
_					Codeine, Morphine,
F	7.7	9.26	Accident	None Reported	Diphenhydramine, 6-MAM
F	4.8	8.2	Accident	None Reported	Ethanol
F	6.2	30.49	Natural	None Reported	Midazolam

F	6.4	27.16	Undetermined	None Reported	Caffeine, Cotinine, Ethanol
-	0.4	27.10	onacterninea		Cyclobenzaprine, 7-
F	5.2	14.55	Natural	Delusion	Aminoclonazepam
F	5.5	17.3	Homicide	None Reported	Caffeine
F	3.2	24.1	Natural	None Reported	None
F	2.5	28.2	Natural	None Reported	None
F	5.5	22.59	Accident	None Reported	None
F	7.1	25.23	Accident	None Reported	Caffeine, Methadone, Citalopram, EDDP, Amphetamine, Methamphetamine Lorazepam, 7-Amino Clonazepam, 11-hydroxy delta-9 THC, delta-9
_	. .	20			carboxy THC, delta-9 THC,
F	6.4	20	Accident	None Reported	Amphetamine, Methamphetamine
M	6.1	8	Natural	None Reported	None
F	5.6	11	Accident	None Reported	Amphetamine, Methamphetamine
Μ	6.3	18	Accident	None Reported	ТНС
м	5.9	6	Accident	None Reported	Amphetamine, Methamphetamine, 6-Monoacetyl Morphine, Codeine, Morphine, Benzoylecgonine
-	F 4	10	Assidant	Nene Departed	Amphetamine, Methamphetamine,
F	5.4	13	Accident	None Reported	Morphine, 6-Monoacetyl Morphine Ethanol, Caffeine, Isopropanol,
М	6.2	10	Natural	Depression, Anxiety	Cotinine, Naloxone
					Caffeine, Alprazolam, Delta-9 Carboxy THC, Trazodone, mCPP,
F	6.1	24	Natural	Lupus, Chronic Pain	Citalopram
			1	Sui Group	
М	3.9	16	Suicide	Depression	Ethanol
				Suicide Ideation	
Μ	5.1	24	Suicide	and Threats	Ethanol
М	6.3	25	Suicide	None Reported	None
				Depression,	
Μ	6.6	22.42	Suicide	Anxiety	Trazodone, 7-Aminoclonazepam
Μ	7.1	18	Suicide	None Reported	None
М	6.7	18.58	Suicide	ADHD, Depression, Suicide Ideation	Amitryptyline
М	4.2	15.17	Suicide	None Reported	Ethanol
М	6.9	16.51	Suicide	None Reported	None
F	6.3	24	Suicide	None Reported	None
F	6.8	43.28	Suicide	None Reported	THC, 7-Amino Clonazepam

F	5.5	18	Suicide	None Reported	Caffeine, Cotinine, Diphenhydramine			
					Ethanol, Hydrocodone,			
F	2.4	18.35	Suicide	None Reported	Hydromorphine			
F	6.6	28	Suicide	MDD	N/A			
F	2	27	Suicide	MDD	N/A			
F	2.1	17	Suicide	MDD	N/A			
F	4	22	Suicide	MDD	N/A			
М	6.7	14	Suicide	None Reported	Fluoxetine, Norfluoxetine			
М	5.9	9	Suicide	None Reported	None			
				OCD, Alcohol and				
F	6.9	27.41	Suicide	Opioid Dependence	N/A			
М	6.8	24.47	Suicide	MDD, ADHD	N/A			
F	4.8	28	Suicide	MDD, OCD	N/A			
М	5.9	19	Suicide	ASD, BD	N/A			
ADHD=Attention Deficit/Hyperactivity Disorder; MDD=Major Depressive Disorder; OCD=Obsessive								
Compulsive Disorder; ASD=Autism Spectrum Disorder; BD=Bipolar Disorder, N/A=Not Available.								

Green-highlighted Subjects= iPSCs were generated from the dermal fibroblasts of these subjects.

Table ST2: Significant gene ontology (GO) (CorrectedPvalue≤0.05; terms CorrectedMFPvalue≤0.05) obtained through gene score resampling (GSR) method of ErmineJ (version 3.2) using the p-value from DESeq2 results (factor:~age+sex+RIN+group). ID=numerical ID of the GO term; Genes# =number of the genes in the GO term; RawScore=ErmineJ-derived score for the GO term; Pval=uncorrected p-value; CorrPvalue=FDR-corrected p-value; MFPvalue=multifunctionality p-value, CorrMFPvalue=p-value after multifunctionality Multifunc=multifunctionality; Green=NPAS4-associated correction; GO terms; Orange=ALDH1A2-associated GO terms; Blue=ALDH1A2- and NAAA-associated GO terms.

Name	ID	Genes #	RawScore	Pval	CorrPvalue	MFPvalue	CorrMFPvalue	Multifunc
Positive regulation of interferon-beta production	GO:0032728	38	1.21907837	1.00E-12	1.29E-09	3.89E-09	1.68E-06	0.802
Regulation of interferon-beta production	GO:0032648	55	1.09966104	1.43E-12	1.54E-09	3.10E-07	9.11E-05	0.843
Positive regulation of type I interferon production	GO:0032481	58	1.1062244	1.00E-12	2.15E-09	1.02E-06	2.44E-04	0.871
Negative regulation of viral genome replication	GO:0045071	44	1.15847562	2.58E-12	2.38E-09	1.44E-10	7.74E-08	0.702
Regulation of type I interferon production	GO:0032479	94	0.98294724	1.00E-12	3.23E-09	4.22E-06	9.10E-04	0.96
Pattern recognition receptor signaling pathway	GO:0002221	84	1.00485783	1.00E-12	6.46E-09	1.05E-04	1.38E-02	0.973
Toll-like receptor signaling pathway	GO:0002224	55	1.07259199	1.70E-11	1.37E-08	2.54E-04	2.78E-02	0.868
Negative regulation of viral process	GO:0048525	73	0.98206521	1.09E-10	7.80E-08	3.35E-07	9.41E-05	0.814
Regulation of viral genome replication	GO:0045069	69	0.91425383	5.69E-08	2.62E-05	4.27E-06	8.90E-04	0.836
Cellular response to xenobiotic stimulus	GO:0071466	54	0.91800513	2.19E-06	7.09E-04	2.27E-06	5.06E-04	0.898
Positive regulation of endothelial cell proliferation	GO:0001938	81	0.83095155	9.61E-06	2.59E-03	1.66E-05	2.91E-03	0.913
Digestive tract development	GO:0048565	40	0.9073861	3.71E-05	6.15E-03	1.00E-12	1.08E-09	0.887
Platelet activation	GO:0030168	48	0.87666977	4.79E-05	7.20E-03	1.78E-05	3.03E-03	0.839
Excitatory postsynaptic potential	GO:0060079	49	0.87707	4.69E-05	7.22E-03	5.83E-10	2.69E-07	0.89
Retinal metabolic process	GO:0042574	17	1.24282696	5.50E-05	8.08E-03	1.50E-05	2.69E-03	0.684
Cellular response to retinoic acid	GO:0071300	51	0.86224105	5.72E-05	8.22E-03	1.85E-10	9.20E-08	0.87
Midgut development	GO:0007494	6	1.87467553	6.00E-05	8.43E-03	7.50E-05	1.08E-02	0.744
Embryonic camera-type eye development	GO:0031076	11	1.36407656	1.75E-04	1.66E-02	4.00E-05	6.01E-03	0.608
Regulation of postsynaptic membrane potential	GO:0060078	76	0.7837523	2.31E-04	2.05E-02	1.54E-07	4.73E-05	0.906
Embryonic digestive tract development	GO:0048566	14	1.23906795	2.30E-04	2.06E-02	1.90E-04	2.19E-02	0.731
Response to retinoic acid	GO:0032526	88	0.76959343	2.60E-04	2.16E-02	1.61E-06	3.70E-04	0.969
Long-term memory	GO:0007616	35	0.89977609	2.69E-04	2.20E-02	1.16E-05	2.21E-03	0.838
Primary alcohol metabolic process	GO:0034308	62	0.80199472	3.66E-04	2.57E-02	1.00E-12	1.62E-09	0.9
Proximal/distal pattern formation	GO:0009954	17	1.12669608	3.90E-04	2.60E-02	1.25E-04	1.55E-02	0.723
Embryonic forelimb morphogenesis	GO:0035115	21	1.05611122	4.70E-04	2.87E-02	2.20E-04	2.49E-02	0.784
Retinoic acid biosynthetic process	GO:0002138	7	1.50579959	5.00E-04	2.99E-02	1.00E-12	3.23E-09	0.52
Forelimb morphogenesis	GO:0035136	25	1.00171502	7.00E-04	3.74E-02	4.60E-04	4.87E-02	0.792
Fc receptor signaling pathway	GO:0038093	44	0.84070362	7.31E-04	3.84E-02	9.06E-05	1.25E-02	0.883
Vitamin A metabolic process	GO:0006776	7	1.4515446	7.60E-04	3.93E-02	1.00E-12	2.15E-09	0.471

Gene symbol	P-value	FDR step up	Ratio	Fold change	LSMean (NPC)	LSMean (Neurons)	Change in Neurons
Neuron Mark			Turio	enunge	(1110)	(r (eurons)	
MAP2	1.22E-10	7.27E-10	0.50	-2.00	20216.47	40372.30	Increased
DLG4	2.08E-13	1.73E-12	0.33	-3.07	1092.41	3356.51	Increased
TUBB3	7.76E-05	2.09E-04	0.46	-2.18	10699.69	23301.64	Increased
Hippocampal	Markers						
ZBTB20	4.64E-06	1.50E-05	0.55	-1.82	2258.07	4102.88	Increased
LHX9	2.65E-02	4.42E-02	0.11	-8.70	99.49	865.57	Increased
ELAVL2	4.86E-05	1.35E-04	0.37	-2.72	1555.09	4223.59	Increased
TSPAN7	2.23E-31	1.02E-29	0.09	-10.67	341.84	3647.89	Increased
CA1 Markers	5						
POU3F1	2.45E-11	1.58E-10	3.72	3.72	671.81	180.51	Decreased
BCL11B	1.51E-04	3.88E-04	0.24	-4.17	121.61	506.50	Increased
WFS1	3.13E-01	3.88E-01	1.16	1.16	823.45	710.76	Unchanged
CA2 Markers	5						
PCP4	1.94E-26	5.78E-25	0.06	-17.20	21.92	376.90	Increased
RGS14	4.78E-05	1.33E-04	2.71	2.71	310.55	114.57	Decreased
CA3 Markers	5						
ELAVL2	4.86E-05	1.35E-04	0.37	-2.72	1555.09	4223.59	Increased
GRIK4	7.24E-24	1.71E-22	0.19	-5.15	97.73	503.64	Increased
SNAP91	1.25E-14	1.19E-13	0.08	-12.22	182.29	2228.27	Increased
SH3GL2	6.26E-26	1.77E-24	0.05	-20.24	73.48	1487.06	Increased
CADPS2	2.38E-10	1.37E-09	0.40	-2.50	403.03	1007.88	Increased
CHGB	1.18E-15	1.28E-14	0.20	-5.01	314.53	1575.08	Increased
CACNA1A	3.44E-07	1.32E-06	0.32	-3.16	102.71	324.72	Increased
LPL	1.30E-19	2.06E-18	16.51	16.51	23864.67	1445.89	Decreased
TGFB2	2.82E-04	6.87E-04	0.15	-6.55	470.78	3082.20	Increased
MYO5B	1.31E-11	8.74E-11	0.35	-2.88	363.62	1046.40	Increased
PKIA	5.83E-12	4.03E-11	0.29	-3.40	2909.73	9897.58	Increased
SNCA	1.29E-06	4.52E-06	0.38	-2.62	749.64	1963.01	Increased
SPOCK1	6.84E-12	4.69E-11	2.94	2.94	5093.39	1732.34	Decreased
HSPA2	6.78E-04	1.54E-03	0.36	-2.75	301.57	829.65	Increased
NEFL	2.39E-03	4.91E-03	0.60	-1.66	7239.41	12038.06	Increased
DKK3	3.68E-30	1.58E-28	0.23	-4.26	1705.69	7268.11	Increased
DG Markers							
PROX1	8.00E-02	1.18E-01	1.63	1.63	743.05	454.89	Unchanged

Table ST3: DESeq2 results for Differentially Expressed Genes (DEGs) in iPSC-derived hippocampal-like neurons (NPC vs Neurons). n=4 for both the NPCs and Neurons.

CALB1	5.27E-08	2.25E-07	5.55	5.55	6930.12	1248.18	Decreased
DOCK10	9.88E-12	6.66E-11	0.21	-4.81	475.82	2286.60	Increased

Table ST4: Differentially expressed genes (DEGs), determined by RNA-Sequencing (RNA-Seq), in iPSCderived hippocampal-like NPCs of suicide deaths (CON vs Sui). n=2/group. Highlighted genes are common in both NPCs and neurons.

	DESeq2 results for hippocampal-like NPCs (CON vs Sui), p≤0.05, FDR≤0.05								
Gene Symbol	P-value	FDR step up	Ratio	Fold change	LSMean(CON)	LSMean(Sui)			
SNORD3B-2	5.29E-88	3.22E-84	0.02	-57.59	68.08	3920.73			
SNORD3B-1	5.29E-88	3.22E-84	0.02	-57.59	68.08	3920.73			
RELN	1.04E-12	4.23E-09	5.55	5.55	3215.45	579.00			
CRH	8.39E-10	2.56E-06	5.00	5.00	866.32	173.37			
CNTN2	3.78E-09	9.22E-06	4.23	4.23	3894.81	920.86			
H4C11	2.68E-08	5.44E-05	0.29	-3.43	900.78	3092.58			
SCUBE1	8.21E-08	1.43E-04	3.31	3.31	3370.64	1019.14			
EMX2OS	3.19E-07	4.86E-04	4.28	4.28	1074.58	251.21			
PARMI	6.48E-07	8.77E-04	2.91	2.91	2925.97	1004.88			
TMTC1	2.13E-06	2.60E-03	2.51	2.51	3019.33	1201.43			
COL3A1	3.03E-06	3.36E-03	0.50	-2.00	8849.73	17657.70			
HMCN1	5.56E-06	5.52E-03	0.36	-2.76	597.42	1649.41			
CNTNAP2	5.89E-06	5.52E-03	2.14	2.14	5905.46	2764.22			
EMX2	7.54E-06	6.57E-03	4.24	4.24	587.40	138.49			
SCG2	1.17E-05	9.50E-03	2.74	2.74	9006.52	3285.05			
OXTR	2.49E-05	1.90E-02	3.41	3.41	515.49	151.01			
PDPR	3.30E-05	2.20E-02	0.46	-2.16	1664.37	3588.05			
H2AC12	3.65E-05	2.20E-02	0.53	-1.87	4910.13	9206.07			
COL8A1	3.66E-05	2.20E-02	2.70	2.70	3610.26	1339.34			
BGN	3.77E-05	2.20E-02	0.34	-2.93	255.28	748.74			
CCZI	3.79E-05	2.20E-02	2.23	2.23	2006.89	901.72			
BLACATI	4.06E-05	2.25E-02	3.49	3.49	688.16	197.13			
PRSS23	5.16E-05	2.65E-02	1.85	1.85	13209.09	7147.09			
FBLN2	5.40E-05	2.65E-02	0.45	-2.24	1125.37	2523.00			
ABCA1	5.43E-05	2.65E-02	2.23	2.23	1888.39	847.99			
FZD5	5.82E-05	2.73E-02	2.58	2.58	809.60	313.30			
IFITM2	6.19E-05	2.78E-02	0.38	-2.62	793.15	2077.36			
UNC5D	6.39E-05	2.78E-02	2.24	2.24	1654.83	738.10			
CCZ1B	7.79E-05	3.28E-02	0.49	-2.06	1171.02	2407.12			
COL12A1	9.57E-05	3.89E-02	0.39	-2.57	1172.34	3017.78			
VAV3	1.10E-04	4.32E-02	2.39	2.39	1332.99	557.65			

Table ST5: Differentially expressed genes (DEGs), determined by RNA-Sequencing (RNA-Seq), in iPSCderived hippocampal-like Neurons of suicide deaths (Con vs Sui). n=2/group. Highlighted genes were common in both NPCs and neurons.

DESEq2 results for hippocampal-like neurons (CON vs Sui), p≤0.05, FDR≤0.05									
		FDR step		Fold					
Gene symbol	P-value	up	Ratio	change	LSMean(CON)	LSMean(Sui)			
SNORD3B-2	8.32E-31	5.89E-27	0.02	-40.71	35.19	1432.48			
SNORD3B-1	8.32E-31	5.89E-27	0.02	-40.71	35.19	1432.48			
COL3A1	1.11E-15	5.23E-12	0.22	-4.50	8656.00	38989.35			
COLIAI	1.69E-15	5.97E-12	0.13	-7.51	2230.48	16757.22			
DCN	4.03E-13	1.14E-09	0.21	-4.86	411.79	2003.27			
IGFBP3	1.57E-11	3.70E-08	0.20	-5.12	229.47	1175.62			
COL5A1	2.42E-11	4.89E-08	0.24	-4.22	944.15	3982.05			
HMCNI	8.95E-11	1.54E-07	0.16	-6.15	113.60	698.99			
THBS1	9.78E-11	1.54E-07	0.23	-4.28	525.45	2251.32			
LUM	1.65E-10	2.33E-07	0.28	-3.57	1128.19	4029.03			
COL6A3	1.96E-10	2.52E-07	0.18	-5.60	942.49	5279.06			
H4C11	4.95E-08	5.83E-05	0.18	-5.57	197.46	1099.07			
PRRXI	1.14E-07	1.18E-04	0.25	-4.02	168.74	678.51			
SNORD97	1.23E-07	1.18E-04	0.27	-3.67	315.25	1156.59			
IFITM2	1.25E-07	1.18E-04	0.23	-4.27	267.81	1144.73			
FBN2	2.65E-07	2.35E-04	0.26	-3.83	499.27	1914.45			
ID1	3.70E-07	3.08E-04	0.27	-3.75	181.85	682.55			
POSTN	5.68E-07	4.46E-04	0.21	-4.81	697.52	3351.59			
CYP26A1	6.00E-07	4.46E-04	0.21	-4.72	100.56	474.93			
NOMO3	7.90E-07	5.59E-04	0.20	-5.09	481.99	2455.69			
FBN1	1.99E-06	1.34E-03	0.35	-2.86	745.52	2134.39			
MME	4.39E-06	2.83E-03	0.17	-5.99	48.15	288.61			
MMP2	5.46E-06	3.36E-03	0.25	-4.01	184.15	738.88			
PDGFRA	6.62E-06	3.90E-03	0.33	-3.07	283.64	870.61			
MGP	9.81E-06	5.55E-03	0.21	-4.86	69.97	339.72			
ALDH1A3	2.90E-05	1.58E-02	0.15	-6.64	59.00	391.60			
COL5A2	3.90E-05	2.04E-02	0.44	-2.28	3432.70	7821.19			
AQP1	4.55E-05	2.30E-02	0.33	-2.99	396.99	1186.18			
CCZIB	5.12E-05	2.50E-02	0.42	-2.41	720.36	1734.82			
CXCL14	9.87E-05	4.65E-02	0.14	-7.23	19.88	143.68			
NLRP2	1.02E-04	4.65E-02	0.28	-3.58	117.21	419.51			
MXRA5	1.05E-04	4.66E-02	0.23	-4.31	73.19	315.56			
TBR1	1.11E-04	4.78E-02	6.39	6.39	165.84	25.95			

Materials and Methods

RNA Extraction and Sequencing

The postmortem CA1 tissues were dissected out from the hippocampal formation and stored in RNAlater solution (Thermofisher # AM7020) at -80°C until RNA extraction. The total RNA was extracted from CA1 tissues using RNeasy Lipid Tissue Mini Kit (Qiagen # 74804) as per manufacturer's instructions. The total RNA from iPSC-derived NPCs and neurons were extracted using RNeasy Mini Kit (Qiagen # 74104). The RNA library preparation was carried out using Ribo-Zero Gold rRNA depletion and TrueSeq Stranded Total RNA Kit (Illumina, San Diego, USA). For 36 samples, 100 bp paired-end sequencing was performed on NovaSeq 6000 platform at the UCI Genomics High Throughput Facility (GHTF). For 14 samples, 125 bp paired-end sequencing was performed on HiSeq 2500 platform at the University of Utah High-Throughput Genomics. The number of read for each sample ranged from 27,277,523 to 65,709,547.

Gene-level Differential Expression (DE) and Gene Ontology (GO) Analyses

Differentially expressed genes (DEGs) analysis was performed in Partek Flow, following five (5) steps: (1) rDNA and mtrDNA contaminants were filtered out from raw fastq files through Bowtie 2 (version 2.2.5). (2) Adaptor sequences were trimmed through Cutadapt-1.12. (3) Alignment of the fastq files was performed through TopHat 2 (version 2.1.0) with default settings [assembly: human-hg19, index: whole genome (administrator)]. (4) Annotation was performed with task "Quantify to annotation model (Partek E/M)" with assembly of human-hg19 and annotation model of RefSeq Transcript 93-2020-02-03. (5) Finally, differentially expressed genes (DEGs) were determined through DESeq2 with default settings. For CA1 tissue DEG analysis, features with minimum value of zero (0) was excluded before DESeq2 analysis. DESeq2 was run with factor of ~Age+Sex+RIN+Group with default parameters. For DEG analysis in iPSC-derived hippocampallike NPCs and neurons, features with minimum value of ≤ 10 were excluded from analysis before DESeq2. DESeq2 was run with default parameters with factors of ~Age+Group (RIN was excluded because RIN was similar in all samples) in CON vs Sui comparison while factor of ~Age+Sex+Type in NPC vs Neurons comparison. The gene ontology (GO) analysis was performed using the gene score resampling (GSR) method as implemented in the ErmineJ (Gillis, Mistry, & Pavlidis, 2010). GSR does not require a threshold for gene selection, but rather uses all the genes with their p-values. The full list of genes with their p-value from the DESeq2 (factor: ~age+sex+RIN+group) was used in the analysis. The following settings were used in the GSR analysis: aspect=biological process, maximum gene set size=100, minimum gene set size=5, maximum iterations=200,000.

Dendritic Spine Morphology Analyses

Briefly, freshly dissected out hippocampal blocks (~1cm³) were immersion fixed in freshly prepared cold 4% paraformaldehyde (in 0.1M Phosphate buffer (PB)) for 1 hour. After 1 hour of fixation, hippocampal blocks were post-fixed in 4% paraformaldehyde + 0.125% glutaraldehyde for 24 hours at 4°C. Later, 350 μ m coronal slices were obtained through vibratome (Leica VT1200). Microscopic 1,1'-dioctadecyl-3,3,3',3'-tetramethylindocarbocyanine perchlorate (DiI)

crystals (Thermofisher # D282) were placed in CA1 regions and incubated in 0.1M PB at 37°C for 72 hours. Dendritic spine images were obtained through a Zeiss LSM 710 confocal microscope using a 63 x oil immersion objective (NA=1.4). The acquired images of dendritic spines were deconvolved using AutoQuant X3 (Bitplane, RRID:SCR_002465) and three-dimensional dendritic spine modeling was performed using Neurolucida 360 (MBF Bioscience, RRID: SCR_016788). 2-3 dendritic segments were analyzed per neuron for both apical and basal dendrites.

Conversion of Skin Fibroblasts into iPSC:

Briefly, dermal fibroblasts were grown from skin biopsies and maintained in fibroblasts media [DMEM, FBS (10%), MEM NEAA, Na-Pyruvate, GlutaMAX, Penicillin-Streptomycin and betamercaptoethanol]. Fibroblasts (in fibroblasts media) were transfected with three episomal plasmids expressing human OCT3/4 and shRNA against p53 (Addgene# 27077: pCXLE-hOCT3/4-shp53-F), L-MYC and LIN28 (Addgene# 27080: pCXLE-hUL), SOX2 and KLF4 (Addgene# 27078: pCXLE-hSK). Fibroblasts (1x10⁶ cells, in fibroblasts media), less than 5 passages, were electroporated with 3 µg of each episomal plasmid through Neon[™] Transfection System 100 µL kit (MPK10096, Thermo Fisher Scientific, MA, USA) according to manufacturer protocol. NeonTM transfection conditions were 1650 V, 10 ms and 3 pulses. Seven-days post-transfection, fibroblasts were replated onto 6-well plates containing mitomycin C-inactivated mouse embryonic fibroblasts (MEF) feeder cells. Next day, fibroblasts media was switched to iPSC media [DMEM/F12 with 20% KOSR, 3% ESC-quality FBS, 20 ng/ml bFGF, 1mM GlutaMAX, 100 µM MEM NEAA, 100 µM 2-mercaptoethanol, and penicillin-streptomycin] which was changed every day until iPSC colonies were ready to be picked. Colonies were manually picked 21 days posttransfection and maintained on Vitronectin XF (Stemcell Technologies Inc, #07180) coated wells with mTeSR Plus feeder-free media (Stemcell Technologies Inc, #100-0276). Pluripotency of iPSCs were characterized through immunostaining of pluripotency markers OCT4, SOX2, SSEA4 and TRA-1-60 (A24881, Thermo Fisher Scientific, MA, USA).

Generation of Hippocampal-like Neural Precursor Cell (NPC) and Neurons:

Briefly, iPSCs were mechanically dissociated and transferred to low-attachment cell culture plates with mTeSR Plus media (with the addition of ROCK inhibitor, 10 μ M) to form embryoid body (EB). After two days, mTeSR Plus media was replaced with N2/B27 media [DMEM/F12/GlutaMax/N2/B27(w/o vitamin A) /Penstrep] supplemented with DKK1 (0.5 μ g/mL), SB431542 (10 μ M), Noggin (0.5 μ g/mL) and cyclopamine (1 μ M) (maintained for 10 days). After 10 days, EBs were transferred onto poly-ornithine/laminin coated plates with N2/B27 media plus laminin (1 μ g/mL). Once rosettes formation was visible, EBs were mechanically dispersed and maintained in N2/B27 media supplemented with 20 ng/mL human basic fibroblasts growth factor (b-FGF) to obtain hippocampal-like NPC. To obtain hippocampal-like neurons, NPCs were plated onto poly-ornithine/laminin coated plates and maintained in neuronal differentiation media [N2B27 media + ascorbic acid (200 μ M) + dibutyryl cyclic-AMP (400 μ M) + BDNF (20 ng/ML) and Wnt3A (5 ng/mL). Wnt3A was discontinued after three weeks and the differentiation was maintained for two more weeks. The iPSC-derived neurons were characterized through RNA-Seq and immunocytochemistry (ICC). The following primary antibodies were used:

MAP2 (ZRB2290, Sigma-Aldrich), beta-Tubulin-III (Tuj1) (801202, BioLegend), vGluT1 (821302, BioLegend), PSD95 (MA1-045, Thermofisher), GABA (A2052, Sigma-Aldrich), GRIK4 (NBP1-76852, Novus Biologicals), PROX1 (925202, BioLegend), and CTIP2 (650601, BioLegend).

References:

Gillis, J., Mistry, M., & Pavlidis, P. (2010). Gene function analysis in complex data sets using ErmineJ. *Nat Protoc*, *5*(6), 1148-1159. doi:10.1038/nprot.2010.78